GoodRx (NASDAQ:GDRX) Sets New 52-Week Low – Should You Sell?

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s stock price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $2.92 and last traded at $2.9750, with a volume of 72887 shares changing hands. The stock had previously closed at $2.97.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $6.00 target price on shares of GoodRx in a report on Monday, August 11th. Raymond James Financial cut GoodRx from a “strong-buy” rating to an “outperform” rating in a report on Friday, August 8th. JPMorgan Chase & Co. lowered their target price on GoodRx from $6.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 11th. TD Cowen decreased their price objective on shares of GoodRx from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Monday, November 10th. Finally, Weiss Ratings downgraded shares of GoodRx from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $5.52.

GoodRx Stock Performance

The firm has a fifty day moving average of $3.85 and a 200-day moving average of $4.19. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81. The firm has a market cap of $947.02 million, a P/E ratio of 31.00, a PEG ratio of 1.48 and a beta of 1.20.

GoodRx (NASDAQ:GDRX) last released its earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The business had revenue of $196.03 million for the quarter, compared to analyst estimates of $195.17 million. During the same quarter in the previous year, the company posted $0.08 earnings per share. The business’s revenue for the quarter was up .4% on a year-over-year basis. GoodRx has set its FY 2025 guidance at EPS. Research analysts predict that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

Insider Buying and Selling

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the company’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $4.00, for a total transaction of $95,084.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.17% of the company’s stock.

Hedge Funds Weigh In On GoodRx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. lifted its holdings in GoodRx by 54.6% during the first quarter. Raymond James Financial Inc. now owns 830,950 shares of the company’s stock worth $3,664,000 after acquiring an additional 293,420 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of GoodRx by 20,956.5% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 14,529 shares of the company’s stock worth $64,000 after purchasing an additional 14,460 shares during the period. Algert Global LLC bought a new position in shares of GoodRx during the 1st quarter valued at about $1,224,000. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of GoodRx by 16.5% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,671,521 shares of the company’s stock valued at $8,324,000 after purchasing an additional 236,896 shares during the period. Finally, XTX Topco Ltd bought a new stake in GoodRx during the 1st quarter worth approximately $315,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.